Concepts (167)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 24 | 2021 | 839 | 5.170 |
Why?
|
| Graft Rejection | 14 | 2021 | 458 | 2.180 |
Why?
|
| Liver Transplantation | 8 | 2021 | 400 | 2.170 |
Why?
|
| Immunosuppressive Agents | 14 | 2021 | 514 | 2.120 |
Why?
|
| Analgesics, Opioid | 5 | 2020 | 498 | 1.940 |
Why?
|
| Transplant Recipients | 6 | 2019 | 109 | 1.680 |
Why?
|
| Kidney Failure, Chronic | 5 | 2020 | 365 | 1.280 |
Why?
|
| Tacrolimus | 5 | 2021 | 127 | 1.160 |
Why?
|
| Graft Survival | 11 | 2019 | 465 | 1.110 |
Why?
|
| Opioid-Related Disorders | 2 | 2020 | 298 | 1.090 |
Why?
|
| Telemedicine | 4 | 2021 | 700 | 1.020 |
Why?
|
| End Stage Liver Disease | 3 | 2021 | 60 | 0.900 |
Why?
|
| Antilymphocyte Serum | 2 | 2016 | 52 | 0.890 |
Why?
|
| Drug Monitoring | 2 | 2021 | 107 | 0.830 |
Why?
|
| Pharmacists | 6 | 2021 | 125 | 0.740 |
Why?
|
| Medication Errors | 5 | 2021 | 116 | 0.710 |
Why?
|
| Cytomegalovirus Infections | 2 | 2017 | 69 | 0.680 |
Why?
|
| Prescription Drug Monitoring Programs | 1 | 2020 | 34 | 0.670 |
Why?
|
| Delivery of Health Care | 2 | 2020 | 445 | 0.650 |
Why?
|
| Ganciclovir | 1 | 2017 | 27 | 0.610 |
Why?
|
| Immunoglobulins | 1 | 2017 | 97 | 0.590 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2017 | 62 | 0.590 |
Why?
|
| Opiate Substitution Treatment | 1 | 2017 | 57 | 0.590 |
Why?
|
| Induction Chemotherapy | 1 | 2017 | 39 | 0.570 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 504 | 0.560 |
Why?
|
| Calcineurin Inhibitors | 1 | 2016 | 24 | 0.530 |
Why?
|
| Adult | 19 | 2021 | 21403 | 0.530 |
Why?
|
| Withholding Treatment | 1 | 2016 | 35 | 0.530 |
Why?
|
| Health Policy | 1 | 2017 | 221 | 0.520 |
Why?
|
| Antiviral Agents | 1 | 2017 | 211 | 0.520 |
Why?
|
| Postoperative Complications | 5 | 2017 | 1615 | 0.510 |
Why?
|
| Sirolimus | 1 | 2016 | 118 | 0.500 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 567 | 0.500 |
Why?
|
| Retrospective Studies | 14 | 2021 | 7277 | 0.480 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 438 | 0.470 |
Why?
|
| Middle Aged | 20 | 2021 | 21147 | 0.470 |
Why?
|
| Humans | 32 | 2021 | 68618 | 0.460 |
Why?
|
| Patient Selection | 1 | 2017 | 592 | 0.450 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 772 | 0.420 |
Why?
|
| Prospective Studies | 6 | 2021 | 3705 | 0.420 |
Why?
|
| Medication Adherence | 5 | 2021 | 335 | 0.410 |
Why?
|
| Male | 22 | 2021 | 37321 | 0.400 |
Why?
|
| Female | 21 | 2021 | 38074 | 0.390 |
Why?
|
| Professional Role | 3 | 2021 | 80 | 0.380 |
Why?
|
| Monitoring, Immunologic | 1 | 2010 | 2 | 0.370 |
Why?
|
| Drug Prescriptions | 1 | 2012 | 135 | 0.370 |
Why?
|
| Hepatorenal Syndrome | 1 | 2010 | 16 | 0.360 |
Why?
|
| Pilot Projects | 3 | 2020 | 1342 | 0.340 |
Why?
|
| Mobile Applications | 2 | 2021 | 138 | 0.310 |
Why?
|
| Risk Factors | 11 | 2017 | 5731 | 0.290 |
Why?
|
| Liver Cirrhosis | 3 | 2017 | 301 | 0.280 |
Why?
|
| Renal Insufficiency | 2 | 2017 | 121 | 0.240 |
Why?
|
| Follow-Up Studies | 5 | 2017 | 3259 | 0.230 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 2 | 2017 | 148 | 0.230 |
Why?
|
| Cohort Studies | 2 | 2020 | 2358 | 0.220 |
Why?
|
| Proportional Hazards Models | 3 | 2018 | 792 | 0.190 |
Why?
|
| Pharmacology, Clinical | 1 | 2021 | 13 | 0.190 |
Why?
|
| Anesthesiologists | 1 | 2021 | 30 | 0.190 |
Why?
|
| Treatment Outcome | 7 | 2021 | 7029 | 0.180 |
Why?
|
| United States | 5 | 2020 | 7367 | 0.180 |
Why?
|
| Insurance Carriers | 1 | 2020 | 9 | 0.180 |
Why?
|
| Delayed-Action Preparations | 1 | 2020 | 120 | 0.180 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 37 | 0.170 |
Why?
|
| Time Factors | 5 | 2018 | 4655 | 0.160 |
Why?
|
| Patient Readmission | 3 | 2016 | 267 | 0.160 |
Why?
|
| Smartphone | 1 | 2019 | 69 | 0.160 |
Why?
|
| Electronic Health Records | 2 | 2019 | 374 | 0.160 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 214 | 0.160 |
Why?
|
| Program Development | 1 | 2019 | 240 | 0.150 |
Why?
|
| Immunization, Passive | 1 | 2017 | 24 | 0.150 |
Why?
|
| Survival Rate | 2 | 2018 | 1056 | 0.150 |
Why?
|
| Preoperative Period | 1 | 2018 | 50 | 0.150 |
Why?
|
| Glomerular Filtration Rate | 2 | 2016 | 274 | 0.150 |
Why?
|
| Health Care Costs | 1 | 2020 | 346 | 0.150 |
Why?
|
| Certification | 1 | 2018 | 66 | 0.150 |
Why?
|
| Healthcare Disparities | 2 | 2018 | 378 | 0.150 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2017 | 52 | 0.150 |
Why?
|
| Cytomegalovirus | 1 | 2017 | 63 | 0.150 |
Why?
|
| No-Show Patients | 1 | 2016 | 9 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2018 | 110 | 0.140 |
Why?
|
| Clinical Protocols | 1 | 2017 | 172 | 0.140 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2016 | 42 | 0.140 |
Why?
|
| Internet | 1 | 2019 | 390 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2020 | 1745 | 0.140 |
Why?
|
| Patient Outcome Assessment | 1 | 2016 | 42 | 0.130 |
Why?
|
| Longitudinal Studies | 5 | 2018 | 1054 | 0.130 |
Why?
|
| Kidney Function Tests | 1 | 2016 | 114 | 0.130 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 951 | 0.130 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 172 | 0.120 |
Why?
|
| Aged | 6 | 2021 | 14862 | 0.120 |
Why?
|
| BK Virus | 1 | 2014 | 17 | 0.120 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 17 | 0.120 |
Why?
|
| Tumor Virus Infections | 1 | 2014 | 32 | 0.120 |
Why?
|
| Opportunistic Infections | 1 | 2014 | 33 | 0.120 |
Why?
|
| Thiazides | 1 | 2013 | 6 | 0.110 |
Why?
|
| Prognosis | 2 | 2016 | 2093 | 0.110 |
Why?
|
| Models, Statistical | 1 | 2017 | 448 | 0.110 |
Why?
|
| South Carolina | 1 | 2020 | 2752 | 0.110 |
Why?
|
| Diuretics | 1 | 2013 | 97 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2014 | 114 | 0.110 |
Why?
|
| Young Adult | 3 | 2019 | 5717 | 0.110 |
Why?
|
| Forms and Records Control | 1 | 2012 | 16 | 0.100 |
Why?
|
| Risk | 2 | 2013 | 563 | 0.100 |
Why?
|
| Anti-Infective Agents | 1 | 2014 | 166 | 0.100 |
Why?
|
| Medical Records | 1 | 2012 | 121 | 0.100 |
Why?
|
| Risk Assessment | 4 | 2021 | 2007 | 0.100 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 292 | 0.100 |
Why?
|
| Blood Glucose | 1 | 2014 | 631 | 0.090 |
Why?
|
| Host vs Graft Reaction | 1 | 2010 | 1 | 0.090 |
Why?
|
| Lypressin | 1 | 2010 | 5 | 0.090 |
Why?
|
| Portasystemic Shunt, Transjugular Intrahepatic | 1 | 2010 | 22 | 0.090 |
Why?
|
| Immunocompromised Host | 1 | 2010 | 55 | 0.090 |
Why?
|
| Vasodilation | 1 | 2010 | 85 | 0.090 |
Why?
|
| Obesity | 1 | 2017 | 1076 | 0.090 |
Why?
|
| Length of Stay | 3 | 2021 | 780 | 0.090 |
Why?
|
| Vasoconstrictor Agents | 1 | 2010 | 107 | 0.090 |
Why?
|
| Hospitals | 1 | 2012 | 265 | 0.090 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2009 | 32 | 0.090 |
Why?
|
| Vitamin D | 1 | 2014 | 516 | 0.090 |
Why?
|
| Antihypertensive Agents | 1 | 2013 | 498 | 0.080 |
Why?
|
| Surveys and Questionnaires | 1 | 2017 | 2800 | 0.080 |
Why?
|
| Veterans | 1 | 2016 | 904 | 0.080 |
Why?
|
| Critical Care | 1 | 2010 | 263 | 0.080 |
Why?
|
| Disease Progression | 1 | 2010 | 1038 | 0.070 |
Why?
|
| Incidence | 3 | 2016 | 1603 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2014 | 1085 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2077 | 0.060 |
Why?
|
| Hypertension | 1 | 2013 | 1535 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2017 | 867 | 0.060 |
Why?
|
| Medication Reconciliation | 1 | 2021 | 18 | 0.050 |
Why?
|
| Ventilators, Mechanical | 1 | 2021 | 13 | 0.050 |
Why?
|
| Erythrocyte Transfusion | 1 | 2021 | 72 | 0.050 |
Why?
|
| Cost Savings | 1 | 2021 | 110 | 0.050 |
Why?
|
| Single-Blind Method | 1 | 2021 | 249 | 0.050 |
Why?
|
| Intensive Care Units | 1 | 2021 | 344 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2021 | 880 | 0.040 |
Why?
|
| Adiposity | 1 | 2017 | 88 | 0.040 |
Why?
|
| Waiting Lists | 1 | 2017 | 104 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2017 | 67 | 0.040 |
Why?
|
| Delayed Graft Function | 1 | 2016 | 39 | 0.030 |
Why?
|
| Appointments and Schedules | 1 | 2016 | 47 | 0.030 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2017 | 52 | 0.030 |
Why?
|
| Bariatric Surgery | 1 | 2017 | 90 | 0.030 |
Why?
|
| Workflow | 1 | 2017 | 100 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2017 | 174 | 0.030 |
Why?
|
| Hospitalization | 1 | 2021 | 978 | 0.030 |
Why?
|
| Health Status Disparities | 1 | 2018 | 326 | 0.030 |
Why?
|
| Weight Loss | 1 | 2017 | 319 | 0.030 |
Why?
|
| Health Status | 1 | 2017 | 429 | 0.030 |
Why?
|
| Glycemic Index | 1 | 2014 | 28 | 0.030 |
Why?
|
| Michigan | 1 | 2014 | 68 | 0.030 |
Why?
|
| Hepacivirus | 1 | 2014 | 90 | 0.030 |
Why?
|
| Hyperkalemia | 1 | 2013 | 21 | 0.030 |
Why?
|
| Adolescent | 2 | 2017 | 8912 | 0.030 |
Why?
|
| Comorbidity | 1 | 2017 | 1426 | 0.030 |
Why?
|
| Potassium | 1 | 2013 | 168 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2014 | 546 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1753 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2016 | 1553 | 0.030 |
Why?
|
| Diabetes Complications | 1 | 2013 | 249 | 0.020 |
Why?
|
| Recurrence | 1 | 2014 | 948 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2014 | 1046 | 0.020 |
Why?
|
| Sex Factors | 1 | 2014 | 1266 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1851 | 0.020 |
Why?
|
| Quality of Life | 1 | 2017 | 1515 | 0.020 |
Why?
|
| Biomarkers | 1 | 2014 | 1593 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2013 | 1451 | 0.020 |
Why?
|